Shattuck Labs
Presence
Shattuck Labs is a company listed under the stock ticker STTK (US).
Executives
View the org chart displaying its 22 main executives
Most searched biographies at Shattuck Labs
- Taylor Schreiber, Chief Executive Officer and Director
- Helen Boudreau, Director
- Neil Gibson, Director
Popular executive movements at Shattuck Labs
- Clay Siegall has joined the company as Director (posted on March 5 2024).
- Kate Sasser has joined the company as Director (posted on March 5 2024).
Create your alert
to follow the executive moves at Shattuck Labs.
Biotechnology
Shattuck Labs has 2,286 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by Shattuck Labs
- Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
- Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
- Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
- Shattuck Labs Announces Participation in Upcoming March Conferences
- Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
- Shattuck Labs | Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
- Shattuck Labs | Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
- Shattuck Labs | Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
- Shattuck Labs | Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid
- View more press releases Close
Social media about Shattuck Labs
- Shattuck Labs on Wikipedia, Google News & Yahoo Finance
- Shattuck Labs on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Taylor Schreiber 
Call Shattuck Labs at +1 91...
